| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.BREAST.2012.09.008 |
| P698 | PubMed publication ID | 23084121 |
| P2093 | author name string | Michael Andersson | |
| Iben Kümler | |||
| Dorte L Nielsen | |||
| Jesper A E Palshof | |||
| P433 | issue | 1 | |
| P921 | main subject | antibody | Q79460 |
| monoclonal antibody | Q422248 | ||
| P304 | page(s) | 1-12 | |
| P577 | publication date | 2012-10-16 | |
| P1433 | published in | The Breast | Q7719928 |
| P1476 | title | Efficacy of HER2-targeted therapy in metastatic breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors | |
| P478 | volume | 22 |
| Q36740744 | A tale of two approaches: complementary mechanisms of cytotoxic and targeted therapy resistance may inform next-generation cancer treatments |
| Q52597562 | A targeted immunotherapy approach for HER2/neu transformed tumors by coupling an engineered effector domain with interferon-γ. |
| Q51727547 | An eco-friendly direct spectrofluorimetric method for the determination of irreversible tyrosine kinase inhibitors, neratinib and pelitinib: application to stability studies. |
| Q36938365 | Anti-HER2 Therapy Beyond Second-Line for HER2-Positive Metastatic Breast Cancer: A Short Review and Recommendations for Several Clinical Scenarios from a Spanish Expert Panel |
| Q54365469 | Assessment of tumor characteristics and factors affecting survival in patients with primary metastatic breast carcinoma: a Multicenter Study of the Anatolian Society of Medical Oncology. |
| Q53241143 | Association between the HER2 Ile655Val polymorphism and response to trastuzumab in women with operable primary breast cancer. |
| Q38093430 | BIM, PUMA, and the achilles' heel of oncogene addiction |
| Q37077422 | Cellular iron metabolism in prognosis and therapy of breast cancer |
| Q33995239 | Clinicopathological variables predicting HER-2 gene status in immunohistochemistry-equivocal (2+) invasive breast cancer |
| Q33691823 | Engineered Multivalency Enhances Affibody-Based HER3 Inhibition and Downregulation in Cancer Cells |
| Q42698976 | Epiregulin Recognition Mechanisms by Anti-epiregulin Antibody 9E5: STRUCTURAL, FUNCTIONAL, AND MOLECULAR DYNAMICS SIMULATION ANALYSES. |
| Q27348830 | Erbb2 is required for cardiac atrial electrical activity during development |
| Q38238613 | Exploring mechanisms of acquired resistance to HER2 (human epidermal growth factor receptor 2)-targeted therapies in breast cancer |
| Q38973014 | Gallium-68-labeled anti-HER2 single-chain Fv fragment: development and in vivo monitoring of HER2 expression |
| Q37636623 | Gasdermin B expression predicts poor clinical outcome in HER2-positive breast cancer |
| Q35211263 | HER2 in solid tumors: more than 10 years under the microscope; where are we now? |
| Q33976964 | HER2-signaling pathway, JNK and ERKs kinases, and cancer stem-like cells are targets of Bozepinib small compound. |
| Q37639917 | Hepatitis B virus X upregulates HuR protein level to stabilize HER2 expression in hepatocellular carcinoma cells. |
| Q26777681 | Human epidermal growth factor receptor 2 positive (HER2+) metastatic breast cancer: how the latest results are improving therapeutic options |
| Q35168105 | Identification of anti-ErbB2 dual variable domain immunoglobulin (DVD-Ig™) proteins with unique activities |
| Q38255064 | Mechanism-based cancer therapy: resistance to therapy, therapy for resistance |
| Q33744198 | Metastatic human epidermal growth factor 2 (HER2/neu) amplified breast cancer with acute fulminant hepatitis responding to trastuzumab, pertuzumab and carboplatin. |
| Q28072513 | Molecular Mechanisms and Translational Therapies for Human Epidermal Receptor 2 Positive Breast Cancer |
| Q33559178 | Molecular Signaling of Progesterone, Growth Hormone, Wnt, and HER in Mammary Glands of Dogs, Rodents, and Humans: New Treatment Target Identification |
| Q39200319 | New protein kinase inhibitors in breast cancer: afatinib and neratinib |
| Q34959996 | Oncogenic alterations in ERBB2/HER2 represent potential therapeutic targets across tumors from diverse anatomic sites of origin |
| Q33740638 | PIK3CA and TP53 gene mutations in human breast cancer tumors frequently detected by ion torrent DNA sequencing |
| Q38132237 | Pertuzumab for the treatment of metastatic breast cancer |
| Q38179024 | Precision treatment for cancer: role of prognostic and predictive markers |
| Q36963554 | Preclinical Evaluation of 18F-Labeled Anti-HER2 Nanobody Conjugates for Imaging HER2 Receptor Expression by Immuno-PET. |
| Q30663382 | Relationship between clinical data and gene expression in the HER2/ErbB2-dependent signaling pathway in patients with acute heart failure. |
| Q47243379 | Resistance to receptor-blocking therapies primes tumors as targets for HER3-homing nanobiologics |
| Q46011982 | SEOM clinical guidelines for the management of metastatic breast cancer 2013. |
| Q36337372 | Safety, pharmacokinetics and efficacy findings in an open-label, single-arm study of weekly paclitaxel plus lapatinib as first-line therapy for Japanese women with HER2-positive metastatic breast cancer |
| Q38253835 | Small molecule tyrosine kinase inhibitors of ErbB2/HER2/Neu in the treatment of aggressive breast cancer. |
| Q30590270 | Strategies for modern biomarker and drug development in oncology |
| Q33822560 | Synergistic effects of various Her inhibitors in combination with IGF-1R, C-MET and Src targeting agents in breast cancer cell lines |
| Q38165164 | Targeted therapies and clinical trials in ovarian cancer |
| Q36771985 | The erbB3- and IGF-1 receptor-initiated signaling pathways exhibit distinct effects on lapatinib sensitivity against trastuzumab-resistant breast cancer cells |
| Q33692847 | Translating extranuclear steroid receptor signaling to clinical medicine |
| Q47573583 | Tumor Uptake of 64Cu-DOTA-Trastuzumab in Patients with Metastatic Breast Cancer. |
| Q54979012 | Utility of a Novel Three-Dimensional and Dynamic (3DD) Cell Culture System for PK/PD Studies: Evaluation of a Triple Combination Therapy at Overcoming Anti-HER2 Treatment Resistance in Breast Cancer. |
| Q39022194 | Validity of immunohistochemistry method in predicting HER-2 gene status and association of clinicopathological variables with it in invasive breast cancer patients. |
| Q38673589 | When Good Turns Bad: Regulation of Invasion and Metastasis by ErbB2 Receptor Tyrosine Kinase |
| Q34048535 | miR-21 Expression in Cancer Cells may Not Predict Resistance to Adjuvant Trastuzumab in Primary Breast Cancer. |
Search more.